ITG and NTP Cooperation - Milestone in Global Security of Supply for Radioisotope Industry

Garching (ots) - ITG Isotope Technologies Garching GmbH (ITG) -
specialist in innovative radioisotopes - expands its nuclear reactor
and technology network in line with its strategy to guarantee global
security of supply.

In May 2012, ITG - a fully-owned subsidiary of ITM Isotopen
Technologien München AG (ITM) based in Germany - and NTP
Radioisotopes SOC Ltd (NTP) - a subsidiary of the South African
Nuclear Energy Corporation (NECSA) - agreed on a substantial
collaboration regarding radioisotopes. The cooperation is an
important milestone in ensuring a reliable supply of high quality
radioisotopes for Africa and Brazil. As a first step, NTP and ITG
have agreed on a technology transfer for the unique isotope ITG Lu-
177 n.c.a. (non carrier added). In addition, ITG will expand its
already well-established global reactor network by cooperating with
NECSA's Safari-1 nuclear reactor.

Lutetium-177 plays a key role in nuclear medicine in the treatment
of neuroendocrine tumors, and has displayed strong growth potential.
In comparison to other production routes, every atom of the ITG Lu-
177 n.c.a. is radioactive. This results in specific activity many
times higher than similar products, therefore rendering treatments
more effective. The contamination with the long lived isomer Lu-177m
is negligible. NTP has in-licensed the production technology and will
hence be the exclusive distribution partner for ITG products in
Africa.

Safari-1 nuclear reactor is one of only five reactors in the
world, which together produce 98% of the world's radionuclides for
the medical sector. Steffen Schuster, CEO of ITM states: "In the
recent past, SAFARI-1 has been instrumental in securing the supply of
radiopharmaceuticals (via NTP) into the world market when reactors
were down due to unforeseen problems. It sends a strong signal to
those companies working with Lu-177-based therapies - global supply
is guaranteed and the agreement serves as proof of the value of our
production expertise.".

ITG is a well-established company in the supply of next generation
isotopes and technology. The company provides highly effective
radioisotopes, such as the ITG Lu-177 n.c.a., the ITG Ge-68/Ga-68
Generator and the ITG W-188/Re-188 Generator, as well as
corresponding customized devices. ITG is renowned for its dedicated
team providing outstanding reliability in both quality and supply.
ITG has an esteemed global network of sales partners and strategic
cooperations.

NTP is recognized as a leading global supplier of radioisotopes.
NTP manufactures a range of radioisotope products for use in
downstream medical devices and procedures as well as in industry.
They have maintained consistent growth in over 60 countries and in
customers served.

The alliance of ITG and NTP will further enhance their
international competitiveness as well as reinforce their prominent
position as a reliable and attractive partner for their customers
worldwide.

For further information and investor enquiries please contact:
ITG Isotope Technologies Garching GmbH,
Dr. Richard Henkelmann,
Managing Director,
+49 89 289-13946,
Richard.Henkelmann@itg-garching.de